Does Cigna Cover Weight Loss Treatment in Maine? A 2026 Guide

Last updated: July 20, 2026

If you have Cigna health insurance in Maine and are exploring weight loss treatment, understanding your coverage can save you time, money, and frustration. Cigna’s pharmacy benefit manager in Maine is Express Scripts (ESI), and its weight loss formulary has an important distinction worth knowing: Zepbound (tirzepatide) was never removed from the ESI formulary, unlike CVS/Caremark (which removed it in July 2025 and is reinstating it October 1, 2026). That ongoing Zepbound access may meaningfully affect which medications are available to you.

This guide covers Cigna’s 2026 weight loss medication coverage in Maine, including Maine-specific prescription rules, the ESI formulary, prior authorization requirements, and your rights as a patient.

Key Facts at a Glance
Insurer: Cigna Health
Pharmacy Benefit Manager (PBM): Express Scripts (ESI)
Zepbound (tirzepatide) status: Never removed from ESI. Available at Tier 3. 4 with PA (key differentiator vs. CVS/Caremark)
Maine parity law (§ 2749-A): Applies to mental health/SUD only. Does not govern weight loss
Maine EPCS: Phentermine & Qsymia (Schedule IV) = EPCS REQUIRED; GLP-1s/Contrave/orlistat = non-scheduled = inapplicable
Cigna PA policy IP0477: Stimulants only. Does not apply to weight loss medications
Key contacts: Cigna 1-800-244-6224 | ESI 1-800-835-3784 | Maine Bureau of Insurance 1-800-300-5000

Check if Your Plan May Cover Weight Loss Treatment →

Does Maine Law Require Cigna to Cover Weight Loss?

Maine’s primary insurance parity statute. Me. Rev. Stat. Ann. tit. 24-A, § 2749-A. Mandates that insurers cover mental health and substance use disorder (MH/SUD) conditions at parity with medical/surgical benefits. Weight loss and obesity are not classified as MH/SUD conditions under § 2749-A, so this parity law does not require Cigna to cover weight loss treatment in Maine.

Weight loss coverage in Maine is instead governed by:

• Affordable Care Act (ACA) essential health benefits (EHB): Marketplace and fully-insured plans must cover preventive obesity screening and intensive behavioral counseling (at no cost-sharing). Prescription weight loss medications are generally not included as a required EHB.
• Plan design: Cigna’s commercial fully-insured plans determine medication coverage through the ESI formulary. Coverage tiers, prior authorization rules, and benefit limits vary by plan.
• ERISA self-funded plans: If your employer self-funds its health plan, federal ERISA preempts Maine’s state insurance mandates, and weight loss coverage is entirely at the employer’s discretion.

Bottom line: whether Cigna covers your weight loss medications in Maine depends on your specific plan design, not a state mandate.

Maine Electronic Prescribing Requirements (EPCS) for Weight Loss Medications

Maine has one of the broadest electronic prescribing controlled substance (EPCS) mandates in the country, covering Schedule II through Schedule V controlled substances under Me. Rev. Stat. Ann. tit. 32, § 13786-A.

For weight loss patients, the practical impact breaks down as follows:

For most Cigna Maine patients seeking GLP-1 medications (Wegovy, Zepbound, Saxenda) or Contrave, EPCS requirements are entirely inapplicable. These are non-scheduled drugs. Only phentermine-based medications trigger the Maine EPCS mandate. When using a telehealth provider such as Klarity, confirm your prescriber is EPCS-certified if phentermine or Qsymia is your target medication.

Cigna / Express Scripts Weight Loss Formulary (Maine, 2026)

Express Scripts manages Cigna’s pharmacy benefits in Maine. Below is the 2026 ESI weight loss formulary with prior authorization and EPCS requirements:

Formulary placement and PA criteria may vary by specific Cigna plan. Verify your benefits by calling the member services number on your Cigna ID card.

Zepbound and Cigna/ESI: Why “Never Removed” Matters

In July 2025, CVS/Caremark removed Zepbound (tirzepatide) from its commercial formulary, affecting members of Aetna and other CVS/Caremark-managed plans. CVS/Caremark announced that Zepbound will be reinstated to its formulary on October 1, 2026.

Express Scripts (ESI). Cigna’s PBM. Took a different path: Zepbound was never removed from the ESI formulary. Cigna/ESI members in Maine with qualifying BMI and a prior authorization approval have had continuous access to Zepbound at Tier 3. 4 throughout 2025 and 2026. This is a meaningful advantage for patients who prefer tirzepatide over semaglutide (Wegovy) or who have already responded well to Zepbound.

If you have Cigna and your provider believes Zepbound is the right medication for you, the ESI formulary’s continued listing may make PA approval more straightforward than it would be under a plan that removed the drug entirely.

Does Cigna’s IP0477 Policy Apply to Weight Loss Medications?

Cigna implemented PA policy IP0477 effective May 15, 2026, requiring prior authorization for all stimulant medications (generic and brand-name). A significant change for ADHD patients. However, IP0477 is a stimulant-only policy and does not apply to weight loss medications.

GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda), Contrave, orlistat, phentermine, and Qsymia are not stimulants. PA requirements that apply to these weight loss medications exist independently of IP0477 and are based on BMI criteria, documentation of a qualified comorbidity, and evidence of lifestyle intervention. Not the IP0477 protocol.

Prior Authorization for Cigna Weight Loss Medications in Maine

Virtually all prescription weight loss medications on the ESI formulary require prior authorization. To improve the likelihood of approval, your provider typically needs to document:

• BMI threshold: BMI ≥ 30 kg/m² (obesity), or BMI ≥ 27 kg/m² with a qualified weight-related comorbidity such as type 2 diabetes, hypertension, hyperlipidemia, or obstructive sleep apnea.
• Prior treatment history: Documentation that the patient has attempted lifestyle modification (diet and exercise) and has not achieved adequate weight loss.
• Medical necessity: A provider note establishing clinical justification for the requested medication.
• Behavioral counseling: Some plans require enrollment in or referral to an intensive behavioral counseling program alongside pharmacotherapy.
• Qsymia-specific. REMS enrollment: Qsymia carries a Risk Evaluation and Mitigation Strategy (REMS) program due to teratogenicity risk. Prescribers must be certified in the REMS program, and female patients of childbearing potential must use effective contraception.

Step Therapy and Formulary Exceptions

Some Cigna plans apply step therapy to weight loss medications, requiring patients to try a lower-tier medication (often orlistat or phentermine) before approving a specialty GLP-1. If step therapy applies to your plan and you believe it is clinically inappropriate, you have the right to request a step therapy exception. Under Maine law, insurers must respond to step therapy exception requests within 72 hours for urgent situations and 30 days for standard requests.

ACA Preventive Coverage: Free Obesity Screening and Counseling

Under the Affordable Care Act, all fully-insured Cigna plans in Maine must cover the following at no cost-sharing (no copay, no deductible) for eligible members:

• BMI screening: Annual body mass index screening for all adults.
• Intensive behavioral counseling: Referral to or direct provision of intensive obesity-focused behavioral counseling for adults with BMI ≥ 30 kg/m² (USPSTF B recommendation).

These preventive services do not require a prior authorization. They represent a no-cost entry point for many patients beginning a weight management journey before proceeding to prescription medications.

How to Verify Your Cigna Weight Loss Coverage in Maine

1. Log into myCigna.com and navigate to the “Coverage & Benefits” section. Search for “weight loss” or “obesity” to review covered services and your specific formulary tier.
2. Call Cigna Member Services at 1-800-244-6224 (the number on your insurance card). Ask specifically about weight loss medication coverage, PA requirements, and whether your plan includes step therapy for GLP-1s.
3. Call Express Scripts at 1-800-835-3784 to verify your specific medication’s formulary tier, PA criteria, and estimated out-of-pocket cost.
4. Confirm EPCS capability with your provider: If phentermine or Qsymia is being considered, your prescriber must be EPCS-certified to issue that prescription in Maine.
5. Request a formulary exception if your preferred medication is not on your plan’s formulary or requires step therapy you believe is clinically unnecessary.

How to Appeal a Weight Loss Coverage Denial

If Cigna denies coverage for a weight loss medication, you have the right to appeal:

1. Review the denial notice: Cigna is required to provide a written explanation of the denial reason, the clinical criteria applied, and the appeals process.
2. Peer-to-peer review: Your prescribing provider may request a direct clinical conversation with Cigna’s medical reviewer. This is often the fastest path to reversal, especially for GLP-1 medications where clinical evidence is strong.
3. Internal appeal: Submit a formal written appeal with supporting clinical documentation (chart notes, BMI records, prior treatment history). Maine law requires Cigna to respond within 30 days for standard appeals and 72 hours for urgent medical situations.
4. Step therapy exception: If denied due to step therapy requirements, submit a formal exception request. Document why the required first-step medication is contraindicated or clinically inappropriate.
5. External independent medical review (IMR) or Maine Bureau of Insurance complaint: If internal appeals are exhausted, you may file for external review or contact the Maine Bureau of Insurance at 1-800-300-5000.

How Klarity May Help with Cigna Weight Loss Coverage in Maine

Klarity Health connects Maine residents with licensed medical providers who specialize in weight management and telehealth prescribing. With more than 2,000+ licensed providers in its network, Klarity may help you:

• Determine whether you may qualify for Cigna coverage of weight loss medications based on your BMI and health history
• Work with a provider experienced in navigating ESI prior authorization requirements for GLP-1 medications
• Access EPCS-certified prescribers if phentermine or Qsymia is clinically appropriate for your situation
• Receive support throughout the PA and appeals process if initial coverage is denied

See if You May Qualify for Weight Loss Treatment →

Frequently Asked Questions

Does Cigna cover Ozempic for weight loss in Maine?

Ozempic (semaglutide injection) is FDA-approved for type 2 diabetes, not obesity. Cigna may cover it for qualifying diabetes patients but typically does not cover it as a weight loss medication. Wegovy (same active ingredient, different dose formulation) is the semaglutide product approved for chronic weight management and is the one covered under the ESI weight loss formulary with PA and BMI criteria.

Is Zepbound covered by Cigna in Maine?

Yes. Zepbound (tirzepatide) remains on the Express Scripts formulary at Tier 3. 4 and was never removed by ESI. Prior authorization and BMI criteria apply. This distinguishes Cigna/ESI from Aetna/CVS Caremark, where Zepbound was removed in July 2025 and is only being reinstated October 1, 2026.

Does Maine’s mental health parity law require Cigna to cover weight loss?

No. Me. Rev. Stat. Ann. tit. 24-A, § 2749-A governs mental health and substance use disorder parity only. Weight loss and obesity are not covered by this statute. Weight loss medication coverage is determined by your specific Cigna plan design and ACA preventive benefit rules.

Do I need an electronic prescription for Wegovy or Zepbound in Maine?

No. GLP-1 medications including Wegovy, Zepbound, and Saxenda are non-scheduled drugs. Maine’s EPCS mandate applies to Schedule II through Schedule V controlled substances only. Non-scheduled medications are not subject to EPCS requirements and may be prescribed through standard telehealth workflows.

What does Cigna’s IP0477 policy mean for my weight loss medications?

IP0477 is a Cigna stimulant prior authorization policy effective May 15, 2026, and it applies exclusively to ADHD stimulant medications. It has no impact on weight loss medications. PA requirements for GLP-1s, Contrave, phentermine, or Qsymia are governed by separate clinical criteria.

Can a telehealth provider prescribe phentermine in Maine through Cigna?

Yes, if the provider is EPCS-certified and licensed in Maine. Phentermine is a Schedule IV controlled substance, which means Maine’s EPCS law requires electronic prescribing. Your provider must hold a valid Maine DEA registration, be EPCS-certified, and phentermine must be appropriate for your clinical profile. Coverage through Cigna/ESI typically requires PA and may be subject to quantity limits.

Key Contacts

• Cigna Member Services: 1-800-244-6224 | myCigna.com
• Express Scripts (ESI): 1-800-835-3784
• Maine Bureau of Insurance: 1-800-300-5000 | maine.gov/pfr/insurance
• Maine DHHS: 1-800-977-6740
• U.S. Department of Labor EBSA (self-funded plans): 1-866-444-3272
• CMS Medicare/Medicaid: 1-800-633-4227

Coverage disclaimer: This article is for informational purposes only and does not constitute insurance or medical advice. Insurance coverage varies significantly by plan type, employer, and individual benefits. Coverage terms, formulary placement, and prior authorization requirements described here reflect general 2026 Cigna/ESI information and may not reflect your specific plan. Always verify your benefits directly with Cigna and Express Scripts before beginning any treatment. Klarity Health does not guarantee insurance coverage for any service or medication.